Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 - Akari…
DNX Biopharmaceuticals and XL-protein Enter into a Shareholder Agreement to Develop and Commercialize Novel Long Acting Biopharmaceuticals.
Irvine, California, and Freising, Germany, February 1, 2016
On…
XL-protein and Easton Pharmaceutical sign license agreement to develop biopharmaceuticals using PASylation® technology
Freising, Germany, and Chengdu, P.R. China, December 17, 2015…